The weekly litigation news digest is live. Subscribe now

IP Verse

High-Purity Quinoline Derivative And Method For Manufacturing Same - EP3524595

The patent EP3524595 was granted to Eisai R&D Management on Aug 10, 2022. The application was filed on Aug 26, 2015 under application number EP19151846A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3524595

EISAI R&D MANAGEMENT
Application Number
EP19151846A
Filing Date
Aug 26, 2015
Status
Granted And Under Opposition
Jul 8, 2022
Publication Date
Aug 10, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Quinline derivative that is easy to remove such impurities by a common purification method such as chromatography and crystallization. The derivative comprises a compound represented by formula (IV) or a salt thereof; an organometallic reagent such as butyllithium, methyllithium, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide; a hydride such as lithium hydride, sodium hydride or potassium hydride; a heterocyclic compound such as imidazole, pyridine, dimethylpyridine, trimethylpyridine or 4-dimethylaminopyridine; or an organic amine such as triethylamine, N,N-diisopropylethylamine or diazabicycloundecene.

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ACCORD HEALTHCAREMay 10, 2023UEXKULL & STOLBERGADMISSIBLE
AECHTERMay 10, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE
GENERICS UKMay 10, 2023RUSSELLADMISSIBLE
MAIWALDMay 10, 2023MAIWALDADMISSIBLE
STADA ARZNEIMITTELMay 10, 2023HAMM & WITTKOPPADMISSIBLE
WELDINGMay 10, 2023HAMM & WITTKOPPADMISSIBLE
HANSENMay 9, 2023MAIWALDADMISSIBLE
TEVA PHARMACEUTICALSMay 9, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
ELKINGTON AND FIFEMay 4, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (41) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2004053908
DESCRIPTIONUS2007004773
DESCRIPTIONUS2007037849
DESCRIPTIONUS2007078159
DESCRIPTIONUS2007117842
DESCRIPTIONWO2006030826
DESCRIPTIONWO2011021597
OPPOSITIONCN107305202
OPPOSITIONEP1683785
OPPOSITIONEP1698623
OPPOSITIONEP1698923
OPPOSITIONEP1777218
OPPOSITIONEP1797881
OPPOSITIONEP1894918
OPPOSITIONEP3524595
OPPOSITIONJP2014174062
OPPOSITIONJP2015034729
OPPOSITIONUS2004053908
OPPOSITIONUS2007004773
OPPOSITIONUS2007037849
OPPOSITIONUS2007078159
OPPOSITIONUS2007117842
OPPOSITIONUS2008214604
OPPOSITIONWO0232872
OPPOSITIONWO2004101526
OPPOSITIONWO2005044788
OPPOSITIONWO2005063713
OPPOSITIONWO2006030826
OPPOSITIONWO2006137474
SEARCHEP1683785
SEARCHEP1698623
SEARCHEP1777218
SEARCHEP1797881
SEARCHEP1894918
SEARCHUS2007117842
SEARCHWO0232872
SEARCHWO2004101526
SEARCHWO2005044788
SEARCHWO2005063713
SEARCHWO2006030826
SEARCHWO2006137474

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents